2024
Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis
Grubman D, Lansky A, Dwyer M, Zivadinov R, Pietras C, Nazif T, Moses J, Shah T, Gambone L, Leon M, Forrest J, Vora A, Parise H, Messé S. Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis. Cardiovascular Revascularization Medicine 2024, 65: 80. DOI: 10.1016/j.carrev.2024.04.179.Peer-Reviewed Original ResearchClinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR Results of a Patient-Level Pooled Analysis
Lansky A, Grubman D, Dwyer M, Zivadinov R, Parise H, Moses J, Shah T, Pietras C, Tirziu D, Gambone L, Leon M, Nazif T, Messé S. Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR Results of a Patient-Level Pooled Analysis. Journal Of The American College Of Cardiology 2024, 84: 712-722. PMID: 39142725, DOI: 10.1016/j.jacc.2024.05.055.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementClinical ischemic strokeAcute brain infarctionDW-MRIReceiver operating characteristicIschemic strokeTranscatheter aortic valve replacement resultBrain infarctionPatient-level pooled analysisC-statisticBrain MRI lesionsAcute ischemic brain injuryDiffusion-weighted magnetic resonance imagingAortic valve replacementIndividual lesion volumesCore laboratory analysisIschemic brain injuryPredicting ischemic strokeMagnetic resonance imagingStroke Prevention TrialMRI lesionsValve replacementDW-MRI acquisitionsPatient-level dataPooled analysis800.09 Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis
Grubman D, Lansky A, Dwyer M, Zivadinov R, Pietras C, Nazif T, Moses J, Shah T, Gambone L, Leon M, Forrest J, Vora A, Parise H, Messé S. 800.09 Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis. JACC Cardiovascular Interventions 2024, 17: s67-s68. DOI: 10.1016/j.jcin.2024.01.234.Peer-Reviewed Original Research
2022
E-19 | Sex-Specific 1-Year Outcomes in Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: A Patient-Level Pooled Analysis of the Disrupt CAD III and CAD IV Studies
Lansky A, Kearney K, Abbott J, Saito S, Hill J, Kereiakes D. E-19 | Sex-Specific 1-Year Outcomes in Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: A Patient-Level Pooled Analysis of the Disrupt CAD III and CAD IV Studies. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100279. DOI: 10.1016/j.jscai.2022.100279.Peer-Reviewed Original Research
2016
Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials
Bouras G, Jhamnani S, Ng VG, Haimi I, Mao V, Deible R, Cao S, Sudhir K, Lansky AJ. Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheterization And Cardiovascular Interventions 2016, 89: 984-991. PMID: 27545721, DOI: 10.1002/ccd.26711.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsLong coronary lesionsTarget lesion failurePercutaneous coronary interventionAcademic Research ConsortiumMean lesion lengthCoronary lesionsXIENCE VCoronary interventionStent thrombosisLesion lengthRate of TLFControl groupSecond generation drug eluting stentsLong lesion groupAdverse cardiac eventsProbable stent thrombosisPrimary outcome measureCoronary stent systemDrug eluting stentsLesion failureCardiac eventsPooled analysisWorse outcomesLesion group
2015
Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials)
Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, Stone GW, Lansky AJ. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). The American Journal Of Cardiology 2015, 117: 186-191. PMID: 26704028, DOI: 10.1016/j.amjcard.2015.10.029.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionStrong independent predictorMajor bleedingMortality rateBivalirudin therapyCoronary interventionIndependent predictorsFemale genderGlycoprotein IIb/IIIa inhibitor treatmentST-segment elevation myocardial infarctionNon-coronary artery bypassPatient-level pooled analysisImpact of bleedingMajor bleeding ratesPronounced clinical benefitOutcomes of patientsAcute coronary syndromeCohort of patientsElevation myocardial infarctionArtery bypassCoronary syndromeMultivariate adjustmentStandard therapyClinical benefitPooled analysis
2014
TCT-605 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 2-Year Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials
Zhao Y, Xu B, Yang Y, Zhang R, Changsheng M, Li H, Huo Y, Lansky A, Leon M, Gao R. TCT-605 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 2-Year Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials. Journal Of The American College Of Cardiology 2014, 64: b176-b177. DOI: 10.1016/j.jacc.2014.07.670.Peer-Reviewed Original Research
2013
TCT-181 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials
Gao R, Xu B, Lansky A, Yang Y, Zhang R, Changsheng M, Li H, Chen S, Han Y, Yuan Z, Huo Y, Li W, Zhao Y, Leon M. TCT-181 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials. Journal Of The American College Of Cardiology 2013, 62: b59. DOI: 10.1016/j.jacc.2013.08.915.Peer-Reviewed Original ResearchIMPACT OF CORONARY CALCIFICATION ON ONE–YEAR OUTCOMES AFTER PCI IN STEMI AND NSTEMI: POOLED ANALYSIS FROM HORIZONS AND ACUITY TRIALS
Genereux P, Maehara A, Kirtane A, Brener S, Palmerini T, Lasalle L, McAndrew T, Lansky A, Mehran R, Mintz G, Stone G. IMPACT OF CORONARY CALCIFICATION ON ONE–YEAR OUTCOMES AFTER PCI IN STEMI AND NSTEMI: POOLED ANALYSIS FROM HORIZONS AND ACUITY TRIALS. Journal Of The American College Of Cardiology 2013, 61: e1716. DOI: 10.1016/s0735-1097(13)61716-7.Peer-Reviewed Original ResearchASSOCIATION BETWEEN CORONARY CALCIFICATION AND BLEEDING AFTER PCI IN ACS: POOLED ANALYSIS FROM HORIZONS-AMI AND ACUITY TRIALS
Genereux P, Maehara A, Kirtane A, Brener S, Palmerini T, Lasalle L, Sanidas E, Tarigopula M, Yadav M, McAndrew T, Fahy M, Lansky A, Mehran R, Mintz G, Stone G. ASSOCIATION BETWEEN CORONARY CALCIFICATION AND BLEEDING AFTER PCI IN ACS: POOLED ANALYSIS FROM HORIZONS-AMI AND ACUITY TRIALS. Journal Of The American College Of Cardiology 2013, 61: e143. DOI: 10.1016/s0735-1097(13)60144-8.Peer-Reviewed Original Research
2011
Impact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials
Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, Lansky AJ, Lincoff AM, Stone GW. Impact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials. JACC Cardiovascular Interventions 2011, 4: 654-664. PMID: 21700252, DOI: 10.1016/j.jcin.2011.02.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsFemaleHealth Status IndicatorsHemorrhageHeparinHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial ReperfusionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRandomized Controlled Trials as TopicRecombinant ProteinsRisk AssessmentRisk FactorsTriageConceptsPercutaneous coronary interventionTIMI major bleedingPatient-level pooled analysisHORIZONS-AMI trialMajor bleedingBlood transfusionSubsequent mortalityRisk scoreHazard ratioIndependent predictorsPooled analysisGlycoprotein IIb/IIIa inhibitorsPercutaneous Coronary Intervention ResultsIIb/IIIa inhibitorsMajor bleeding ratesTIMI major bleedTIMI minor bleedingRespective hazard ratiosArtery bypass graftRisk score groupsHigh-risk groupRisk of patientsIsolated hematomasMajor bleedsLate mortality
2010
Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW, Investigators S. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1220-1228. PMID: 21232715, DOI: 10.1016/j.jcin.2010.07.017.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicAspirinClopidogrelConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsProportional Hazards ModelsRandomized Controlled Trials as TopicRiskRisk Reduction BehaviorSirolimusTiclopidineTime FactorsConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsAdverse cardiac eventsTarget vessel failureCardiac eventsMyocardial infarctionSPIRIT IIProbable stent thrombosisAcademic Research ConsortiumEverolimus-eluting stentsVessel failureSignificant reductionLesion revascularizationPES patientsRevascularization eventsIII trialsClinical outcomesEE patientsStent thrombosisPooled analysisCumulative ratePersistent reductionSPIRIT IIIPatientsStentsCOMPARISON OF EVEROLIMUS-ELUTING AND PACLITAXEL-ELUTING CORONARY STENTS IN PATIENTS UNDERGOING MULTI-VESSEL STENTING: POOLED ANALYSIS FROM THE SPIRIT III AND SPIRIT IV RANDOMIZED TRIALS
Kereiakes D, Sudhir K, Hermiller J, Lansky A, Doostzadeh J, Pierson W, Su X, Gordon P, Stone G. COMPARISON OF EVEROLIMUS-ELUTING AND PACLITAXEL-ELUTING CORONARY STENTS IN PATIENTS UNDERGOING MULTI-VESSEL STENTING: POOLED ANALYSIS FROM THE SPIRIT III AND SPIRIT IV RANDOMIZED TRIALS. Journal Of The American College Of Cardiology 2010, 55: a140.e1317. DOI: 10.1016/s0735-1097(10)61318-6.Peer-Reviewed Original ResearchA pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.
Seth A, Serruys PW, Lansky A, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, Stone GW. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention 2010, 5: 788-94. PMID: 20142192, DOI: 10.4244/eijv5i7a132.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPaclitaxelProsthesis DesignRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsTAXUS paclitaxel-eluting stentTarget vessel failureAngiographic late lossLate lossDiameter stenosisIII studyPooled analysisSPIRIT IIAdverse cardiac eventsSegment late lossStent late lossCoronary artery diseaseEES groupCardiac eventsArtery diseaseFemale patientsPES groupPatient levelClinical dataXIENCE VStent typeTwo-year analysisWomen
2009
5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents
Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R. 5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents. Journal Of The American College Of Cardiology 2009, 54: 894-902. PMID: 19712798, DOI: 10.1016/j.jacc.2009.04.077.Peer-Reviewed Original ResearchConceptsBare metal stentsTarget vessel revascularizationStent thrombosisRate of deathMyocardial infarctionVessel revascularizationPooled analysisAcademic Research Consortium definitionsPatient-level pooled analysisDrug-eluting stent implantationArterial healing responseComposite of deathProbable stent thrombosisLong-term safetyDrug-eluting stentsLate stent thrombosisClinical outcomesRandomized trialsStent implantationSuperior efficacyBMS groupThrombosisHealing responseSES groupStents